Showing 7241-7250 of 8649 results for "".
- NEI Publishes Town Hall Report on Cell-Based Products for Treating Retinal Diseasehttps://modernod.com/news/nei-publishes-town-hall-report-on-cell-based-products-for-treating-retinal-disease/2481618/Stem cell-based therapies hold great promise for replacing lost or damaged cells in the eye and restoring vision, according to The National Eye Institute, which published its Town Hall Report on cell-based products for treating retinal disease. The NEI has published "Stem cell sources a
- Researchers Discover Small-Molecule Drugs with Potential Clinical Utility in the Treatment of Retinal Diseaseshttps://modernod.com/news/researchers-discovere-small-molecule-drugs-with-potential-clinical-utility-in-the-treatment-of-retinal-diseases/2481616/In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP). The study, titled, “
- C. Light Receives FDA Clearance for Retinal Eye Movement Monitor, Retitrackhttps://modernod.com/news/c-light-receives-fda-clearance-for-retinal-eye-movement-monitor-retitrack/2481615/C. Light Technologies announced it has received 510(k) clearence from the FDA for the Retitrack, which is designed to provide new understanding and insight into oculomotor function via the retina, providing concrete and objective metrics to medical professionals. The
- Oculus Incorporates New Subsidiary in Indiahttps://modernod.com/news/oculus-incorporates-new-subsidiary-in-india/2481614/Oculus has incorporated Oculus Medical Devices India as its 12th international subsidiary as of May 1, 2023. Located in Mumbai, Oculus India, aims to provide cutting-edge medical equipment to the Indian market while maintaining the high standards and quality that Oculus is known for. Sr
- Researchers Found a Way to Reactivate Dormant Cells in the Retinahttps://modernod.com/news/researchers-found-a-way-to-reactivate-dormant-cells-in-the-retina/2481610/There's new hope for potentially restoring vision in patients suffering from degenerative retinal disease, thanks to work by researchers at Université de Montréal (UdeM). Published this week in Proceedings of the National Academy of Sciences, the research was
- International Ophthalmology Panel Calls for Recognizing and Treating Childhood Myopia as a Diseasehttps://modernod.com/news/international-ophthalmology-panel-calls-for-recognizing-and-treating-childhood-myopia-as-a-disease/2481607/Responding to one of the greatest eye health issues in a generation, nine internationally recognized pediatric ophthalmologists have come together to call for greater recognition of childhood myopia as a disease and earlier treatment of children. Their perspectives are now available as a white pa
- FDA Clears Centricity Vision’s ZEPTOLink IOL Positioning Systemhttps://modernod.com/news/fda-clears-centricity-visions-zeptolink-iol-positioning-system/2481592/Centricity Vision announced it has received 510(k) clearance from the FDA for the ZEPTOLink IOL Positioning System. The new platform integrates the ZEPTO precision pulse capsulotomy technology with any phacoemulsification system to streamline cataract surgery.
- Julie Schornack, OD, Named First Female President of Marshall B. Ketchum Universityhttps://modernod.com/news/julie-schornack-od-named-first-female-president-of-marshall-b-ketchum-university/2481585/Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution in Fullerton, California has introduced Julie A. Schornack, OD, MEd, as its next president to lead the university. Dr. Schornack is the first female p
- Precision Eye Therapy for Dogs Ready for Human Clinical Developmenthttps://modernod.com/news/precision-eye-therapy-for-dogs-ready-for-human-clinical-development/2481576/A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with retinitis pigmentosa, according to a university news release. Simon Petersen-Jones, professor and Donald R. Myers and Wil
- EssilorLuxottica Unveils 4-Year Clinical Trial Results of its Essilor Stellest Lens athttps://modernod.com/news/essilorluxottica-unveils-4-year-clinical-trial-results-of-its-essilor-stellest-lens-at-arvo-at/2481572/EssilorLuxottica presented the 4-year clinical trial results of its Essilor Stellest lens for myopia control at the 2023 ARVO annual meeting in New Orleans. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial ey